ESO, CNIO AND NRCO
CONFERENCE ON
FAMILIAL CANCER

19-20 May 2016
Madrid, Spain

Chairs:
R. Eeles, UK
W.D. Foulkes, CA
M. Robledo, ES
H. Vasen, NL
FOREWORD

The ESO, CNIO and NRCO Conference on Familial Cancer aims to present the advances in this field from a multidisciplinary point of view. Familial cancer has become an important challenge for oncologists, geneticists, molecular biologists, and other professionals, due to its implications not only at individual but also at the familial and social level. Along the last years, new approaches have allowed to increase our knowledge about the genes responsible for familial cancer, as well as their biological functions, which is essential to find an appropriate treatment in each case. The next generation sequencing is extensively used in the search of causal mutations, but it represents a new challenge regarding the interpretation of variants, many of which must be classified as of unknown significance.

Biannually the Conference brings together leading basic and translational researchers and clinicians involved in the diagnosis, treatment and follow-up of patients with familial cancer. These meetings help to establish connections among professionals that in turn promote progress in the understanding and treatment of these diseases. Besides the lectures from international experts, young scientists can present their work as short lectures and posters. This format aims to facilitate extensive discussion of current issues and stimulate new ideas.

R. Eeles, W.D. Foulkes, M. Robledo, H. Vasen, NL
Conference Chairs

LEARNING OBJECTIVES

• Selection criteria, landscape of breast and ovarian cancer genes, and clinical management
• Genetics and clinical management of hereditary colorectal cancer
• Therapeutic strategies in the era of personalized medicine
• Translating genetic risk factors to the surveillance and clinical management of prostate cancer
• Rare cancers: Gastric cancer, pancreatic cancer, tuberous sclerosis, Gorlin syndrome, PTEn and related diseases, multiple endocrine neoplasia type 1, among others
• Implications of applying next generation sequencing to the diagnosis

MAIN TOPICS

• Breast and ovarian cancer
• Colon and prostate cancer
• Rare cancers
• Implications of applying next generation sequencing to the diagnosis
FACULTY

A. Antoniou
University of Cambridge, UK

S. Aretz
Institute of Human Genetics, University of Bonn, DE

I. Blanco
Hospital Germans Trias i Pujol, Barcelona, ES

F. Carneiro
Ipatimub-Institute of Molecular Pathology and Immunology, University of Porto, PT

P. Devilee
Leiden University Medical Centre, NL

R. Eeles
NHS Trust and the Institute for Cancer Research, Sutton, UK

W.D. Foulkes
Lady Davis Institute for Medical Research, Montreal, CA

E. Maher
University of Cambridge, UK

M. Martin
Hospital General Universitario Gregorio Marañón, Madrid, ES

A. Osorio
Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, ES

N. Ratner
Children’s Hospital Medical Center, Cincinnati, US

M. Robledo
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, ES

J.R. Sampson
Cardiff University and University Hospital of Wales, Cardiff, UK

S. Syngal
Dana Farber Cancer Institute, Boston, US

G.D. Valk
UMC Utrecht Cancer Center, NL

H. Vasen
Leiden University Medical Centre, NL

L. Walker
Oxford John Radcliffe Hospital, UK
THURSDAY, 19 MAY

9:00 Welcome and introduction
J. Benítez, ES

OPENING LECTURE

9:15 Hereditary cancer syndromes. Overview
M. Robledo, ES

SESSION 1 - BREAST AND OVARIAN CANCER

9:45 Selection criteria and clinical management
L. Walker, UK

10:10 Landscape of breast cancer genes
P. Devilee, NL

10:35 Ovarian cancer. Other genes beyond BRCAs
A. Osorio, ES

11:00 Coffee-break and poster viewing

11:30 How is breast and ovarian cancer susceptibility modulated?
A. Antoniou, UK

11:55 Therapeutic strategies in the era of personalized medicine
M. Martin, ES

12:20 Short communications (up to 3, 10 minutes)

13:15 Lunch and poster view

SESSION 2 - COLON AND PROSTATE CANCER

15:30 Hereditary colorectal cancer. From dominant to recessive genetic models
S. Aretz, DE

15:55 Clinical management of hereditary colorectal cancer syndromes
S. Syngal, US

16:15 Prostate cancer. Translating genetic risk factors to the surveillance and clinical management
R. Eeles, UK

16:40 Coffee-break and poster view

SESSION 3 - CLINICAL CASES (17:15 - 18:30)

18:30 End of the session
FRIDAY, 20 MAY

SESSION 4 - OTHER CANCER SYNDROMES I

9:00  Genetic and clinical management of pancreatic cancer
      H. Vasen, NL

9:25  Multiple endocrine neoplasia type 1
      G. Valk, NL

9:50  Germline DICER1 mutations. Phenotypic landscape
      W.D. Foulkes, CA

10:15 Short oral communications (up to two)

10:40 Coffee-break and poster view

SESSION 5 - OTHER CANCER SYNDROMES II

11:15 Hereditary gastric cancer
      F. Carneiro, PT

11:40 NF1, a RASopathy gene commonly involved in cancer
      N. Ratner, US

12:05 Hereditary renal cancer
      E. Maher, UK

12:30 Tuberous sclerosis as a model for targeted therapy
      J.R. Sampson, UK

12:55 Short oral communications (up to 2)

13:25 Lunch

14:45 Short oral communications (up to 2)

SESSION 6 - IMPLICATIONS OF APPLYING NEXT GENERATION SEQUENCING TO THE
DIAGNOSIS AND ROUND TABLE DISCUSSION

15:15 - 15:45
Speakers: I. Blanco, ES - P. Devilee, NL and W.D. Foulkes, CA

Topics to discuss:

• Next Generation sequencing for diagnosis: WES/Whole genome versus gene panels. PRO and CONS
  W.D. Foulkes, CA

• VUS: a challenge at the bench
  P. Devilee, NL

• Genetic counseling
  I. Blanco, ES

15:45 Open discussion

16:30 Closing remarks
DEADLINE FOR SUBMISSION: 6 MARCH 2016

Abstracts will be assessed for oral or poster presentation at the conference, and for publication on the event-dedicated website.

Participants are invited to submit an abstract on familial cancer, in one of the following categories:

- Diagnostic and prognostic biomarkers
- Case report
- Tumour biology
- Experimental and molecular therapeutics
- Approaches to cancer gene discovery

The acknowledgement of receipt of the abstract will immediately follow the submission. The outcome will be notified to the first author who will be required to register to the conference (early registration deadline 30 March 2016).

For further instruction, please visit www.eso.net.
GENERAL INFORMATION

ORGANISING SECRETARIAT
European School of Oncology, Via Turati, 29, 20121 Milan, Italy

Organisation  Registration
Daniela Mengato - dmengato@eso.net Laura Richetti - lrichetti@eso.net

ONLINE REGISTRATION
Registration may be carried out online at www.eso.net or by returning the enclosed registration form

REGISTRATION
Registration includes participation in all sessions, a copy of the programme and access to the event-dedicated website, coffee breaks and lunches as indicated in the programme.

<table>
<thead>
<tr>
<th></th>
<th>Early (by 30 March)</th>
<th>Late (by 30 April)</th>
<th>On-site (after 30 April)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration fee</td>
<td>EUR 260</td>
<td>EUR 300</td>
<td>EUR 400</td>
</tr>
<tr>
<td>Club ESO Members</td>
<td>EUR 200</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CANCELLATION OF REGISTRATION OR REPLACEMENT
(applicable for individual registrations)
Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee less handling charges of EUR 100 will be refunded after the event, provided that the cancellation is received before 22 April 2016. Replacements will be possible till 30 April 2016.

CONFIRMATION OF REGISTRATION
Registration will be confirmed by email, by fax or by mail.

VENUE
Ateneo de Madrid
Calle del Prado 21, Madrid, Spain
www.ateneodemadrid.com

OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.

BADGE
The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.

INSURANCE
The organisers bear no responsibility for ontoword events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.

CME ACCREDITATION CERTIFICATES
Participants will be entitled to receive a certificate of attendance at the close of the event by completing and submitting the on-line evaluation questionnaire. Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). Information on the status of the applications can be obtained from the organising secretariat.
REGISTRATION FORM

ESO, CNIO AND NRCO CONFERENCE ON FAMILIAL CANCER
19-20 May 2016, Madrid, Spain

Please fill in this form in BLOCK LETTERS and send by the deadline to:
European School of Oncology - Laura Richetti - Piazza Indipendenza 2 - 6500 Bellinzona - Switzerland
Tel: +41 91 8250950 - Fax: +41 91 8250953 - E-mail: lrichetti@eso.net

ONLINE REGISTRATION IS AVAILABLE AT: WWW.ESO.NET

PARTICIPANT'S DETAILS

Dr.          Prof.          Mr.          Mrs.
Surname         Name
Institute          Department
Street
Zip Code         Town           Country
Phone             Fax             Mobile
Email
Date of birth     Birth date (town and country)
Profession
Specialisation     Main field
VAT number (compulsory for self-employed persons)
Fiscal code (Italian residents only)

If your invoice details are different to those above, please complete the following section:

Invoice contact details
Address
Phone             Email
VAT number (compulsory for self-employed persons)
Fiscal Code (Italian residents only)

REGISTRATION

Early
(by 30 March)
Late
(by 30 April)
On-site
(after 30 April)
Registration fee
EUR 260
EUR 300
EUR 400
Club ESO Members
EUR 200

PAYMENT DETAILS

The registration is processed when payment accompanies the form (credit card details or copy of bank transfer)

Visa/Mastercard
Card Number
Expire date
CV2 code
Holder's name: and signature

BANK TRANSFER
with no cost to the beneficiary (please provide a copy of the bank transfer):
Bank:
Account holder:
Number:
IBAN:
Reference:

I authorize the European School of Oncology to use my personal data according to what is specified in Article 13 DLGS 196, available at www.eso.net or on request at fax number +39 02 8546 4545.

Signature  Date